The stock of Alaunos Therapeutics Inc (NASDAQ: TCRT) has increased by 46.94 when compared to last closing price of 1.47. Despite this, the company has experienced a 34.10% gain in its stock price over the last five trading sessions. investorplace.com reported 2023-12-18 that Alaunos Therapeutics (NASDAQ: TCRT ) stock is up on Monday despite a lack of news from the clinical-stage oncology-focused cell therapy company. There are no new press releases or filings with the Securities and Exchange Commission (SEC) that explain why the stock is up today.
Is It Worth Investing in Alaunos Therapeutics Inc (NASDAQ: TCRT) Right Now?
The 36-month beta value for TCRT is also noteworthy at -0.74. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for TCRT is 1.38M, and at present, short sellers hold a 3.75% of that float. The average trading volume of TCRT on April 02, 2025 was 13.52K shares.
TCRT’s Market Performance
TCRT stock saw an increase of 34.10% in the past week, with a monthly gain of 37.58% and a quarterly increase of 17.39%. The volatility ratio for the week is 29.21%, and the volatility levels for the last 30 days are 9.89% for Alaunos Therapeutics Inc (TCRT). The simple moving average for the past 20 days is 40.61% for TCRT’s stock, with a -22.39% simple moving average for the past 200 days.
Analysts’ Opinion of TCRT
Many brokerage firms have already submitted their reports for TCRT stocks, with Wells Fargo repeating the rating for TCRT by listing it as a “Overweight.” The predicted price for TCRT in the upcoming period, according to Wells Fargo is $3 based on the research report published on October 04, 2022 of the previous year 2022.
TCRT Trading at 34.60% from the 50-Day Moving Average
After a stumble in the market that brought TCRT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.57% of loss for the given period.
Volatility was left at 9.89%, however, over the last 30 days, the volatility rate increased by 29.21%, as shares surge +44.97% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +20.00% upper at present.
During the last 5 trading sessions, TCRT rose by +34.10%, which changed the moving average for the period of 200-days by -77.96% in comparison to the 20-day moving average, which settled at $1.5400. In addition, Alaunos Therapeutics Inc saw 13.39% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TCRT starting from Vieser Jaime, who sale 3,000 shares at the price of $2.01 back on Dec 31 ’24. After this action, Vieser Jaime now owns 25,894 shares of Alaunos Therapeutics Inc, valued at $6,022 using the latest closing price.
Vieser Jaime, the Director of Alaunos Therapeutics Inc, proposed sale 3,000 shares at $2.17 during a trade that took place back on Dec 31 ’24, which means that Vieser Jaime is holding shares at $6,510 based on the most recent closing price.
Stock Fundamentals for TCRT
Current profitability levels for the company are sitting at:
- -1236.33 for the present operating margin
- -39.67 for the gross margin
The net margin for Alaunos Therapeutics Inc stands at -1963.5. The total capital return value is set at -2.72. Equity return is now at value -141.73, with -102.49 for asset returns.
Currently, EBITDA for the company is -4.81 million with net debt to EBITDA at 0.15. When we switch over and look at the enterprise to sales, we see a ratio of 295.95. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.30.
Conclusion
In summary, Alaunos Therapeutics Inc (TCRT) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
